Lifevantage Corp. 10-Q Summary: Quarter Ended September 30, 2010
Business Context and Reporting Period
This filing covers the quarterly period ended September 30, 2010, for Lifevantage Corp., a dietary supplement company primarily marketing Protandim and LifeVantage TrueScience Anti-Aging Cream through network marketing and direct-to-consumer channels. The company operates in the U.S., Japan, and Mexico. As of November 4, 2010, 71,314,323 shares of common stock were outstanding.
Key Financial Metrics
| Metric | Q3 2010 | Q3 2009 |
|---|---|---|
| Net Sales | $6,443,349 | $1,857,997 |
| Gross Profit | $5,423,214 | $1,545,023 |
| Gross Margin | 84% | 83% |
| Operating Income | $344,769 | ($3,008,489) |
| Net Income | $715,193 | $2,865,546 |
| Cash and Equivalents | $2,257,060 | $605,261 |
| Working Capital | $29,077 | Not Reported |
| Total Liabilities | $17,758,542 | Not Reported |
| Derivative Liabilities | $14,010,029 | Not Reported |
Cash Flow: Net cash provided by operating activities was $641,651, a significant improvement from a net cash use of $1,634,478 in the prior year period. Investing activities used $7,939, and financing activities provided $0.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 247% year-over-year, driven by expansion in U.S. and Japan network marketing channels.
- Operating Performance: The company moved from an operating loss of $3.0 million in Q3 2009 to an operating profit of $344,769 in Q3 2010.
- Net Income Decline: Despite operational improvements, net income decreased 75% to $715,193. This was primarily due to a $4.2 million decrease in non-cash gains from the change in fair value of derivative liabilities.
- Expense Shifts: Sales and marketing expenses rose 69% due to higher distributor commissions. Conversely, general and administrative expenses fell 37% due to reduced headcount and legal fees.
- Liquidity: Working capital improved from a deficit of $2.1 million at June 30, 2010, to a positive $29,077 at September 30, 2010.
Guidance, Outlook, Risks, and Unusual Items
Outlook: Management forecasts that cash on hand will be sufficient to fund operations through September 30, 2011. The company intends to convert remaining short-term debentures and related derivative liabilities into common stock in the second quarter of fiscal 2011, which is expected to further improve working capital.
Unusual Items: The financial results are heavily influenced by the accounting treatment of derivative liabilities (embedded conversion options and warrants). A $1.8 million non-cash gain on the change in fair value of these liabilities contributed to net income, though this gain was significantly lower than the $6.0 million gain recorded in the prior year.
Risks and Contingencies:
- Internal Controls: Management concluded that disclosure controls and procedures were not effective due to material weaknesses, including inadequate oversight of accounting functions and lack of formal policies. Remediation is planned by June 30, 2011.
- Derivative Volatility: Net income is sensitive to stock price volatility due to the fair value accounting of derivative liabilities.
- Product Concentration: The business relies significantly on a single product (Protandim).
- Investment Liquidity: The company holds $425,000 in auction rate preferred securities (ARPS) which have been affected by liquidity crises, though a repurchase agreement is in place.
Investor Verification Checklist
- Verify the sustainability of the 84% gross margin as the company expands internationally.
- Monitor the conversion of convertible debentures and the resulting dilution to existing shareholders.
- Assess the progress of remediation efforts regarding material weaknesses in internal controls over financial reporting.
- Review the valuation assumptions (volatility, stock price) used to calculate the $14 million derivative liability.
- Confirm the liquidity status of the $425,000 investment in auction rate preferred securities.